Literature DB >> 2940684

D-penicillamine: chemistry and clinical use in rheumatic disease.

H E Howard-Lock, C J Lock, A Mewa, W F Kean.   

Abstract

The discovery of D-penicillamine and its uses in medicine are reviewed. Chemical-physical properties are discussed, and the molecular structure of D-penicillamine and several of its reaction products are illustrated. Examples of its three main types of biochemical reactions--sulfhydryl-disulfide exchange, thiazolidine formation, and metal chelation are included. Trials of D-penicillamine in RA patients are reviewed critically. The administration of the drug is discussed in detail, including dosages, clinical and laboratory responses, patterns of adverse side effects or toxicity, drug-induced autoimmune diseases, indications and contraindications, and the monitoring and management of patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940684     DOI: 10.1016/0049-0172(86)90022-3

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  12 in total

1.  D-penicillamine in the therapy of ankylosing spondylitis.

Authors:  K Tytman; K Bernacka; S Sierakowski
Journal:  Clin Rheumatol       Date:  1989-09       Impact factor: 2.980

Review 2.  Immunotoxic side-effects of drug therapy.

Authors:  J A Mitchell; E M Gillam; L A Stanley; E Sim
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

Review 3.  The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis.

Authors:  L E Hart; P Tugwell
Journal:  Postgrad Med J       Date:  1989-12       Impact factor: 2.401

4.  Determination of IgA- and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy.

Authors:  M Nakano; M Ueno; S Nishi; S Suzuki; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 5.  Prospects of immunotherapy for rheumatoid arthritis.

Authors:  B A t Hart; H G Otten
Journal:  Pharm World Sci       Date:  1995-11-24

Review 6.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

7.  Thyroid function and immune profile in rheumatoid arthritis. A controlled study.

Authors:  A P Andonopoulos; V Siambi; M Makri; M Christofidou; C Markou; A G Vagenakis
Journal:  Clin Rheumatol       Date:  1996-11       Impact factor: 2.980

8.  [Bacterial osteitis. Special considerations in immunocompromised patients].

Authors:  C Niedhart; O Miltner; K-W Zilkens; F U Niethard
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

Review 9.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

10.  Effect of thiol compounds on human complement component C4.

Authors:  S Edmonds; A Gibb; E Sim
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.